跳至主要内容
临床试验/IRCT20170728035349N1
IRCT20170728035349N1尚未招募3 期

Evaluation of the radioprotective effects of famotidine in reducing the hematologic complications of esophageal and cardiac cancers chemoradiation.

Zanjan University of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
30 years 至 75 years(—)
性别
All

入选标准

  • All patients with non-metastatic esophageal cancer and non-metastatic cardiac cancer aged 30 to 75 years who are candidates for radiotherapy and do not receive PPIs and other H2-blocker antagonists.
  • Aged 30 to 75 years old
  • Being candidates for chemo radiotherapy
  • Do not receive PPIs and other H2-blocker antagonists.

排除标准

  • Patients who die during the project.
  • Patients who are unable to continue treatment due to the severity of treatment complications.
  • Patients who are unable to continue treatment due to the severity of treatment complications.
  • Need to use PPI family drugs during the treatment process

研究者

相似试验